Clinical trials: Islet Cell Carcinoma
Gastrinoma, Zollinger Ellison Syndrome
The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid
Patients with Zollinger-Ellison Syndrome suffer from ulcers of the upper gastrointestinal tract, higher than normal levels of gastric acid, and tumors of the pancreas known as non-beta islet cell tumors.
- Trial name
- NCT00001191
- Testing
- Pantoprazole, Omeprazole
- Where
- United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cancer
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005860
- Testing
- floxuridine, leucovorin calcium, oxaliplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroendocrine, Neuroendocrine Tumor
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine…
- Conditions
- Neuroendocrine, Neuroendocrine Tumor, Neuroendocrine Cancer, Neuroendocrine Carcinoma
- Trial name
- NCT02038738
- Testing
- 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Ochsner Health System
Pancreatic Ductal Adenocarcinoma, Ampullary Carcinoma
Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy
This is a monocentric, prospective, randomized controlled trial comparing the safety and efficacy of laparoscopic pancreaticoduodenectomy (LPD) versus open pancreaticoduodenectomy (OPD).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Ampullary Carcinoma, Distal Cholangiocarcinoma, Duodenal Adenocarcinoma
- Trial name
- NCT07328607
- Testing
- Open Pancreaticoduodenectomy, Laparoscopic Pancreaticoduodenectomy
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Minia University
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer
- Trial name
- NCT00002947
- Testing
- indium In 111 pentetreotide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yale University
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
- Trial name
- NCT00427349
- Testing
- AMG 706, octreotide
- Where
- 112 sites in United States
- Volunteers
- 46 people
- Sponsor
- Eastern Cooperative Oncology Group
Hypercalcemia, Familial Primary Hyperparathyroidism
Cinacalcet to Treat Familial Primary Hyperparathyroidism
This study will evaluate the benefits and side effects of a new medication called Cinacalcet for treating patients with primary hyperparathyroidism associated with multiple endocrine neoplasia type 1 (MEN1) or type 2A (MEN2A).
- Trial name
- NCT00325104
- Testing
- Parathyroid hormone testing, Serum calcium testing
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Neuroendocrine Tumor Carcinoid, Neuroendocrine Tumor of Pancreas
68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET
In gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs), radical surgery provides good long-term outcome and low recurrence rates.
- Conditions
- Neuroendocrine Tumor Carcinoid, Neuroendocrine Tumor of Pancreas, Gep Net
- Trial name
- RGS-GEP-NET (NCT05448157)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- European Institute of Oncology
Carcinoma, Carcinoma, Renal Cell
Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.
The primary objective of this study is to analyse the concentration dopamine and serotonin in thrombocytes of patients with renal cell carcinoma and neuro-endocrine tumours compared to the concentrations of these catecholamines…
- Conditions
- Carcinoma, Carcinoma, Renal Cell, Neuroendocrine Tumors, Carcinoid Tumor
- Trial name
- BANN (NCT01398306)
- Testing
- Blood sampling by vena punction.
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- University Medical Center Groningen
Neuroendocrine Tumor, Carcinoid Tumor
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
The purpose of this research study is to determine the effectiveness of AMG 479 against carcinoid and pancreatic neuroendocrine tumors. AMG 479 is an antibody that is made in the laboratory.
- Conditions
- Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT01024387
- Testing
- AMG 479
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of sapanisertib and ziv-aflibercept in treating patients with solid tumors that have come back (recurrent) and have spread to another place in the body (metastatic) or…
- Conditions
- Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma
- Trial name
- NCT02159989
- Testing
- Sapanisertib, Ziv-Aflibercept
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
The purpose of this study is evaluate the efficacy and safety of FOLFIRINOX in patients with gastroenteropancreatic high-grade neuroendocrine carcinomas.
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer, Neuroendocrine Carcinomas of Pancreas, Islet Cell Carcinoma
- Trial name
- NCT03042780
- Testing
- FOLFIRINOX, Granulocyte colony-stimulating factor (G-CSF)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected…
- Conditions
- GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
- Trial name
- NCT07165132
- Testing
- RYZ401
- Where
- 14 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- RayzeBio, Inc.
Neuroendocrine Carcinoma, Islet Cell Carcinoma
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Objectives: Primary endpoint: -Assess the clinical activity of RAD 001 plus depot octreotide as defined by progression free survival (PFS) duration defined by RECIST criteria in treated and untreated patients with metastatic…
- Trial name
- NCT00113360
- Testing
- RAD001, Octreotide Depot
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer, Advanced Breast Cancer
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib.
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer
- Trial name
- NCT00428220
- Testing
- sunitinib
- Where
- 113 sites in United States, Argentina and 15 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the…
- Conditions
- Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
- Trial name
- NCT02595424
- Testing
- Capecitabine, Carboplatin, Cisplatin
- Where
- 673 sites in United States
- Volunteers
- 67 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Neuroendocrine Tumors
Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-tumor and anti-virus protein for injection in treating patients with advanced neuroendocrine tumors who have failed standard treatment or are…
- Trial name
- NCT02455596
- Testing
- Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Neuroendocrine Tumors
Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma
This study is a real-world clinical study. It is expected to include 20 patients with first-line and second-line gastrointestinal pancreatic neuroendocrine carcinoma who will be treated with irinotecan liposomes combined with…
- Trial name
- NCT06485739
- Testing
- Irinotecan liposomes combined with cisplatin/carboplatin
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Estrogen Receptor-positive Breast Cancer, Gastrinoma
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
This phase II trial studies how well real-time pharmacokinetic therapeutic drug monitoring works in preventing stomatitis from developing in patients with hormone receptor positive breast cancer, pancreatic neuroendocrine tumors…
- Conditions
- Estrogen Receptor-positive Breast Cancer, Gastrinoma, Glucagonoma, HER2-negative Breast Cancer
- Trial name
- NCT02273752
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Emory University
Pancreatic Neuroendocrine Carcinoma
Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II
This study is the first randomized, open-label, national, multicenter, phase II study assessing the efficacy and safety of OCLU in subjects with pretreated progressive pancreatic, inoperable, somatostatin receptor positive, well…
- Trial name
- OCCLURANDOM (NCT02230176)
- Testing
- Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate
- Where
- France
- Volunteers
- 84 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris